FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	00() 0. 0.10		00	pany mor	00.0							
	Address of F		2. Issuer Name and Ticker or Trading Symbol Roivant Sciences Ltd. [ROIV]									Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Ramaswamy Vivek														Director		X	10% Owr	ier
(Last) (First) (Middle) PO BOX 20860					3. Date of Earliest Transaction (Month/Day/Year) 12/27/2023									Officer (give title Other (specify below) below)				
					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)					Form filed by More than One Reporting												Person	
COLUMB	SUS O	Н	43220	İ	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													the '
			Table I - No	n-Deriv	ative	Sec	curities Ac	quired, [Disp	osed o	f, or Be	nefi	cially Ow	ned				
1. Title of Security (Instr. 3)					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned		6. Ownership Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial
					, ,	(Month/Day/Year)		Code	v	Amount	(A) (D)	or	Price	Following R Transaction (Instr. 3 and	Reported (I) (Ins		tr. 4) (Ownership Instr. 4)
Common S	12/27/2	27/2023			M ⁽¹⁾⁽²⁾⁽³⁾		275,2	.27	A	(1)(2)(3)	55,063,337(6)		D					
Common Shares 12/27								F ⁽⁴⁾		133,9	11	D	\$11.58	54,929,426(6)		(6) D		
			Table II -				irities Acq s, warrants							ied				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefic Owned Followin Reporte	ve es ially ng	10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title		ount or mber of ares		Transaction((Instr. 4)	tion(s)		
Capped Value Appreciation Rights	(1)(2)(5)	12/27/2023		М			611,393 ⁽¹⁾⁽²⁾	(1)(2)	0	3/31/2026	Common Shares	273	3,490(1)(2)	\$6.4 ⁽¹⁾⁽²⁾⁽⁵⁾	7,132,9	921 ⁽⁵⁾	D	
Capped Value Appreciation	(1)(3)	12/27/2023		М			251,538 ⁽¹⁾⁽³⁾	(1)(3)	0	3/31/2026	Common Shares	1,	,737 ⁽¹⁾⁽³⁾	\$11.5 ⁽¹⁾⁽³⁾	11,570	0,769	D	

Explanation of Responses:

- 1. Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at \$12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
- 2. On December 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.
- 3. On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.
- 4. Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs.
- 5. In the event the fair market value of a Common Share is less than \$9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.
- 6. Includes an award of restricted stock covering Common Shares that is fully vested.

By: /s/ Steve Roberts, as

12/29/2023 Attorney-in-Fact for Vivek

Ramaswamy

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.